Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus-Reference-Cited by-同舟云学术

Potent Bispecific Neutralizing Antibody Targeting Glycoprotein B and the gH/gL/pUL128/130/131 Complex of Human Cytomegalovirus

Published:2021-02-17 Issue:3 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Su Hang¹²,Ye Xiaohua²,Freed Daniel C.³,Li Leike²,Ku Zhiqiang²,Xiong Wei²,Gao Peng²,Liu Xinli⁴,Montgomery Diana³,Xu Weifeng³,Espeseth Amy S.³,Wang Dai³^ORCID,Ma Ningning¹,Fu Tong-Ming²,Zhang Ningyan²^ORCID,An Zhiqiang²^ORCID

Affiliation:

1. Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China

2. Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA

3. Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA

4. University of Houston College of Pharmacy, Houston, Texas, USA

Abstract

Human cytomegalovirus (HCMV) is a ubiquitous pathogen that can cause developmental disorders following congenital infection and life-threatening complications among transplant patients. Potent neutralizing monoclonal antibodies (MAbs) are promising drug candidates against HCMV infection.

Funder

Merck

Welch Foundation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02422-20

Reference54 articles.

1. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection

2. Human cytomegalovirus (HCMV)—revised;Schottstedt V;Transfusion Med Hemother,2010